報價延遲最少15分鐘:2025/02/03 20:42 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.596 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.36/-0.31
|
|
企業價值
61.50M
|
| 資產負債 |
|
每股賬面淨值
-0.22
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
775.30K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/03 20:42 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. |